International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Strok...(elops them into Western mainstream medic...),Health

Date:9/27/2007

elops them into Western mainstream medicine. Moleac also develops innovative technologies and medical products in-licensed from Europe and the US, and markets them in Asia. Focusing on patients' greatest needs and specific unmet medical needs, Moleac drives research, development and registration for a pipeline of drugs and devices in various stages of development. Moleac seeks partners to bring these products to market and will continue to evaluate new opportunities.

Moleac's first product derived from Traditional Chinese Medicine, NeuroAid(TM), has gained market approval in two countries in 2006 and will be available to stroke sufferers around the world in 2007-2008. Moleac also plans the launch of a smoking cessation therapy that will reach key global markets in 2007.

About CHIMES Society

CHIMES Society is an international partnership of Key Opinion Leaders in stroke whose objective is to establish new stroke treatments. Members include physicians, academics, and clinicians, several of which are renowned neurologists from Europe and Asia. The team received a grant from the National Medical Research Council (NMRC) of Singapore to undertake the study over a period of two years. For further information visit http://www.chimes-society.org .

DISCLOSURE NOTICE: The information contained in this release is as of September 24, 2007. Moleac assumes no obligation to update any forward- looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about the potential benefits of NeuroAid(TM) that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed as well as their decisions rega
'/>"/>

SOURCE Moleac Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients